[ CAS No. 14527-41-4 ] {[proInfo.proName]}

Name: 14527-41-4|5-Thiazolecarboxylic acid|97%
Brand: Ambeed
SKU: A212356
Price: 14.0 USD
Availability: InStock
Rating: 91 (22 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 14527-41-4

Structure of 14527-41-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 14527-41-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 14527-41-4 ]

SDS Specification

Alternatived Products of [ 14527-41-4 ]

Product Details of [ 14527-41-4 ]

CAS No. :	14527-41-4	MDL No. :	MFCD03428539
Formula :	C₄H₃NO₂S	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	YZVFSQQHQPPKNX-UHFFFAOYSA-N
M.W :	129.14	Pubchem ID :	84494
Synonyms :

Calculated chemistry of [ 14527-41-4 ]

Physicochemical Properties

Num. heavy atoms :	8
Num. arom. heavy atoms :	5
Fraction Csp3 :	0.0
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	29.07
TPSA :	78.43 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.51 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.66
Log Po/w (XLOGP3) :	0.81
Log Po/w (WLOGP) :	0.84
Log Po/w (MLOGP) :	-0.77
Log Po/w (SILICOS-IT) :	1.55
Consensus Log Po/w :	0.62

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-1.55
Solubility :	3.66 mg/ml ; 0.0283 mol/l
Class :	Very soluble
Log S (Ali) :	-2.04
Solubility :	1.18 mg/ml ; 0.00915 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-0.63
Solubility :	30.3 mg/ml ; 0.235 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.96

Safety of [ 14527-41-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 14527-41-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 14527-41-4 ]
Downstream synthetic route of [ 14527-41-4 ]

[ 14527-41-4 ] Synthesis Path-Upstream 1~9

1
[ 32955-22-9 ]
[ 14527-41-4 ]

Yield	Reaction Conditions	Operation in experiment
57%	With hydrogenchloride; sodium hydroxide In ethanol	The 5-[α-hydroxy-3-(naphth-2-ylmethoxy)benzyl]thiazole used as a starting material was obtained as follows: A mixture of ethyl thiazole-5-carboxylate (8.5 g), 2N sodium hydroxide solution (28 ml) and ethanol (50 ml) was stirred at ambient temperature for 2.5 hours. The mixture was concentrated and partitioned between diethyl ether and water. The aqueous layer was acidified by the addition of 2N hydrochloric acid solution and extracted with methylene chloride (6*50 ml). The combined extracts were dried (MgSO₄) and evaporated to give thiazole-5-carboxylic acid (4 g, 57percent), m.p. 214°-216° C.

Reference： [1] Patent: US5089513, 1992, A,

2
[ 79265-30-8 ]
[ 14527-41-4 ]

Reference： [1] Patent: US5883102, 1999, A,

3
[ 288-47-1 ]
[ 124-38-9 ]
[ 14527-41-4 ]
[ 14190-59-1 ]

Reference： [1] Journal of the American Chemical Society, 2010, vol. 132, # 26, p. 8858 - 8859

4
[ 32955-22-9 ]
[ 14527-41-4 ]

Reference： [1] Recueil des Travaux Chimiques des Pays-Bas, 1953, vol. 72, p. 262,267
[2] Helvetica Chimica Acta, 1942, vol. 25, p. 375
[3] Journal of Physical Chemistry, 1948, vol. 52, p. 729,736, 737
[4] Journal of Chemical Research, 2011, vol. 35, # 5, p. 313 - 316

5
[ 3034-55-7 ]
[ 14527-41-4 ]

Reference： [1] Recueil des Travaux Chimiques des Pays-Bas, 1954, vol. 73, p. 325,329

6
[ 288-47-1 ]
[ 124-38-9 ]
[ 14527-41-4 ]
[ 14190-59-1 ]

Reference： [1] Journal of the American Chemical Society, 2010, vol. 132, # 26, p. 8858 - 8859

7
[ 186581-53-3 ]
[ 14527-41-4 ]
[ 14527-44-7 ]

Reference： [1] Recueil des Travaux Chimiques des Pays-Bas, 1953, vol. 72, p. 262,267
[2] Helvetica Chimica Acta, 1947, vol. 30, p. 1865,1868

8
[ 14527-41-4 ]
[ 35272-15-2 ]
[ 61291-21-2 ]

Reference： [1] Patent: US6472404, 2002, B1,

9
[ 14527-41-4 ]
[ 35272-15-2 ]
[ 61291-21-2 ]

Reference： [1] Patent: US6472404, 2002, B1,

[ 14527-41-4 ] Synthesis Path-Downstream 1~88

1
[ 186581-53-3 ]
[ 14527-41-4 ]
[ 14527-44-7 ]

Reference： [1]Recueil des Travaux Chimiques des Pays-Bas,1953,vol. 72,p. 262,267

2
[ 3034-55-7 ]
[ 14527-41-4 ]

Reference： [1]Recueil des Travaux Chimiques des Pays-Bas,1954,vol. 73,p. 325,329

3
[ 32955-22-9 ]
[ 14527-41-4 ]

Reference： [1]Recueil des Travaux Chimiques des Pays-Bas,1953,vol. 72,p. 262,267
[2]Journal of Chemical Research,2011,vol. 35,p. 313 - 316

4
thiazole-2,5-dicarboxylic acid [ No CAS ]
[ 14527-41-4 ]

Reference： [1]Helvetica Chimica Acta,1953,vol. 36,p. 138,141
[2]Helvetica Chimica Acta,1953,vol. 36,p. 138,141

5
[ 14527-41-4 ]
[ 541-41-3 ]
C₇H₇NO₄S [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1991,vol. 34,p. 2176 - 2186
[2]Journal of the American Chemical Society,2009,vol. 131,p. 5994 - 6002
[3]Journal of Natural Products,2010,vol. 73,p. 151 - 159

6
[ 14527-41-4 ]
[ 3290-99-1 ]
2-(4-methoxyphenyl)-5-thiazol-5-yl-[1,3,4]oxadiazole [ No CAS ]

Reference： [1]Tetrahedron Letters,2006,vol. 47,p. 105 - 108

7
[ 14527-41-4 ]
[ 130062-64-5 ]
[ 908856-06-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4420 - 4423

8
[ 14527-41-4 ]
[ 108-86-1 ]
[ 1826-13-7 ]

Reference： [1]Journal of the American Chemical Society,2006,vol. 128,p. 11350 - 11351
[2]Journal of Organic Chemistry,2010,vol. 75,p. 1550 - 1560

9
[ 4930-98-7 ]
[ 14527-41-4 ]
5-([1,2,4]triazolo[4,3-a]pyridin-3-yl)thiazole [ No CAS ]

Reference： [1]Tetrahedron Letters,2007,vol. 48,p. 2237 - 2240

10
[ 14527-41-4 ]
[ 123066-64-8 ]
4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]thiazole-5-carboxanilide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 9457 - 9466
[2]Patent: US6348480,2002,B1 .Location in patent: Page column 29

11
[ 14527-41-4 ]
[ 1117-97-1 ]
[ 898825-89-3 ]

Yield	Reaction Conditions	Operation in experiment
65%	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 16h;	Example 131VStep 1. Thiazole-5-carboxylic acid methoxy-methyl-amide (155)[0373] Thiazole-5-carboxylic acid (2g, 15.48mmol), HBTU (14g, 38.8mmol), and DIEA (16mL, 92.88mmol) were dissolved in DMF (5OmL) and stirred at rt until all starting material had been consumed. O,N-Dimethyl-hydroxy1amine (6g, 61.92mmol) was then added to the reaction mixture and stirred for 16 hours. The reaction was then evaporated to dryness, and purified on silica gel to produce compound 155 (1.7g, 65% yield). H1-NMR (DMSO d6): 9.30 (m, 1H), 8.50 (m, 1H), 3.76 (m, 3H), 3.30 (m, 3H).

Reference： [1]Patent: WO2006/76529,2006,A1 .Location in patent: Page/Page column 158

12
[ 14527-41-4 ]
[ 35272-15-2 ]
[ 61291-21-2 ]

Yield	Reaction Conditions	Operation in experiment
		Thiazole-5-carboxylic acid (Example 69) was prepared according to the method described in WO97/14687, and 5-methyl-thiazole-2-carboxylic acid (Example 61) was prepared analogously. 2-Methyl-thiazole-4-carboxylic acid (Example 74) was prepared by analogy to the method of W. R.

Reference： [1]Patent: US6472404,2002,B1

13
[ 32955-22-9 ]
5-[α-hydroxy-3-(naphth-2-ylmethoxy)benzyl]thiazole [ No CAS ]
[ 14527-41-4 ]

Yield	Reaction Conditions	Operation in experiment
57%	With hydrogenchloride; sodium hydroxide; In ethanol;	The 5-[alpha-hydroxy-3-(naphth-2-ylmethoxy)benzyl]thiazole used as a starting material was obtained as follows: A mixture of <strong>[32955-22-9]ethyl thiazole-5-carboxylate</strong> (8.5 g), 2N sodium hydroxide solution (28 ml) and ethanol (50 ml) was stirred at ambient temperature for 2.5 hours. The mixture was concentrated and partitioned between diethyl ether and water. The aqueous layer was acidified by the addition of 2N hydrochloric acid solution and extracted with methylene chloride (6*50 ml). The combined extracts were dried (MgSO4) and evaporated to give thiazole-5-carboxylic acid (4 g, 57%), m.p. 214-216 C.

Reference： [1]Patent: US5089513,1992,A

14
[ 14527-41-4 ]
[ 112888-43-4 ]
[ 75-04-7 ]
N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl) N-ethylamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In water; acetone; acetonitrile;	The <strong>[14527-41-4]thiazole-5-carboxylic acid</strong> used as starting material was obtained as follows:- A mixture of 6-bromomethyl-3,4-dihydro-2-methylquinazolin-4-one (prepared as described in Example 3; 10 g), anhydrous ethylamine (7.9 ml) and acetonitrile (250 ml) was stirred rapidly at laboratory temperature for 4 hours. The mixture was evaporated to dryness, the residue was dissolved in water, filtered and the filtrate was evaporated. The residue was triturated in acetone to give N -(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)- N -ethylamine, as its hydrobromide salt 8.5 g), m.p. >260C.

Reference： [1]Patent: EP239362,1991,B1

15
[ 14527-41-4 ]
[ 41125-73-9 ]

Yield	Reaction Conditions	Operation in experiment
92%	With thionyl chloride; at 80℃; for 5h;Sealed tube;	)In a sealed tube a solution of <strong>[14527-41-4]5-thiazolecarboxylic acid</strong> (400 mg, 3.10 mmol) in thionyl chloride (2.3 mL) was heated at 80C for 5h. The mixture was then concentrated under reduced pressure (twice co-evaporated with toluene) to provide intermediate (77a) (422 mg, 2.87 mmol, 92%) as a yellow solid which was used without further purification.
	With thionyl chloride; In 1,2-dichloro-ethane;	5-Chloroformylthiazole is prepared from 5 g of <strong>[14527-41-4]5-thiazolecarboxylic acid</strong> in 80 cm3 [lacuna] 1,2-dichloroethane. The mixture is refluxed and 34.2 g of thionyl chloride are added dropwise.
		5.25 g of 5-chloroformylthiazole are thus obtained and employed crude. 5-Thiazolecarboxylic acid is prepared according to Erlenmeyer, von Meyenburg, Helvetica Acta, 29, 204 (1937).

Reference： [1]Patent: WO2018/60481,2018,A1 .Location in patent: Page/Page column 184
[2]Patent: US6194426,2001,B1
[3]Patent: US6194426,2001,B1
[4]Journal of Medicinal Chemistry,2009,vol. 52,p. 3047 - 3062
[5]Journal of Chemical Research,2011,vol. 35,p. 313 - 316
[6]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 6218 - 6223
[7]Journal of Medicinal Chemistry,2019,vol. 62,p. 2154 - 2171

16
[ 79265-30-8 ]
[ 14527-41-4 ]

Yield	Reaction Conditions	Operation in experiment
	With n-butyllithium; In hexane;	(a) 5-Thiazolecarboxylic acid 2-(Trimethylsilyl)thiazole (2 g, 12.7 mmol) in ether (10 ml) was added dropwise to a solution of n-butyllithium (1.43M in hexane, 9.33 ml) in ether (20 ml) over 20 min. at -78 C., stirred for 1 h and quenched with solid carbon dioxide. The mixture was allowed to warm to room temperature over 16 h, diluted with 10% sodium hydroxide and extracted twice with ethyl acetate. The aqueous layer was acidified with ice-cold dilute HCl, extracted with ethyl acetate, the organic extract washed with brine, dried over sodium sulphate and evaporated to give a pale yellow solid (870 mg), 1H NMR (d6 -DMSO) 13.58 (1H, br. s), 9.33 (1H, s), 8.45 (1H, s).

Reference： [1]Patent: US5883102,1999,A

17
[ 14527-41-4 ]
[ 75-65-0 ]
[ 942631-50-7 ]

Yield	Reaction Conditions	Operation in experiment
40.3%	With diphenyl phosphoryl azide; triethylamine; at 90℃; for 12h;	1.1 tert-butyl thiazo 1-5 -ylcarbamate A mixture of DPP A (31.1 g, 113 mmol), Et3N (23.70 mL, 170 mmol) and <strong>[14527-41-4]thiazole-5-carboxylic acid</strong> (8.0 g, 61.9 mmol) in tert-BuOH (190 mL) was heated to 90 C for 12 h in a 500 mL round-bottomed flask. After cooling, the solvent was evaporated in vacuo. The residue was diluted with water. The aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic phase was washed with brine, dried, concentrated under reduced pressure to give crude product. The crude product was purified by column chromatography on silica gel (EA/heptane=l/10) to give the title compound (5.0 g, 24.97 mmol, 40.3%) as a white solid. LC-MS: m/z 201 (M+H), RT=1.74 min.
	With diphenyl phosphoryl azide; triethylamine; for 8h;Heating / reflux;	Preparation of the Starting Materials; Method 1; 1 ,3-Thiazol-5-amine; To a solution of l,3-<strong>[14527-41-4]thiazole-5-carboxylic acid</strong> (728 mg, 5.6 mmol) in tert-BuOH (19 mL) was added Et3N (2.4 mL, 17 mmol) and DPPA (2.5 mL, 11.3 mmol) and the resulting dark red solution was heated to reflux for 8 hours. After cooling, EtOAc was added, and the organic layer washed with saturated NaHCO3 solution, water, brine, and dried (MgSO4). Evaporation of the solvents under reduced pressure afforded tert-butyl l,3-thiazol-5- ylcarbamate (500 mg), which was used in the next step without any further purification, m/z: 201.

Reference： [1]Patent: WO2014/41175,2014,A1 .Location in patent: Page/Page column 54-55
[2]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 406 - 412
[3]Patent: WO2007/71955,2007,A1 .Location in patent: Page/Page column 47

18
[ 14527-41-4 ]
[ 104863-67-4 ]
C₆H₂F₃NO₃S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 3456 - 3461

19
[ 14527-41-4 ]
[ 17721-00-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 4794 - 4797

20
[ 14527-41-4 ]
[ 1089660-96-7 ]
[ 891259-14-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 5528 - 5532

21
[ 14527-41-4 ]
[ 1027255-35-1 ]
[ 1027253-87-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 1206 - 1209

22
[ 14527-41-4 ]
[ 658700-12-0 ]
[ 1129249-94-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 773 - 777

23
[ 14527-41-4 ]
[ 79-19-6 ]
[ 1170672-95-3 ]

Yield	Reaction Conditions	Operation in experiment
		Intermediate 12: 5-(1 ,3-Thiazol-5-yl)-1 ,2-dihvdro-3H-1 ,2,4-triazole-3-thioneA mixture of 1 ,3-<strong>[14527-41-4]thiazole-5-carboxylic acid</strong> (0.194 g, 1.5 mmol), HOBT (0.230 g, 1.500 mmol) and DIC (0.234 ml, 1.500 mmol) in THF (11 ml) was stirred at room temperature for 4 min. Hydrazinecarbothioamide (137 mg, 1.500 mmol) was added to the reaction mixture and the reaction mixture was heated at 1000C for 5 min in a microwave reactor. The reaction mixture was evaporated to dryness. Ethanol (6 ml) and aqueous 2M NaOH (6.00 ml, 12.00 mmol) were added and the mixture was heated at 1500C for 10 min in a microwave reactor. Aqueous 5M HCI was added to the reaction mixture to give pH ca. 5, then the solution was extracted with ethyl acetate (3 x 15ml). The organic phases were combined, dried with MgSO4, filtered and evaporated under vacuum to dryness to give the title compound; MS: ES+ m/z: 185 [MH+] at RT 1.3 min. C5H4N4S2 requires 184 (analysed by LCMS A).

Reference： [1]Patent: WO2009/87218,2009,A1 .Location in patent: Page/Page column 37

24
[ 14527-41-4 ]
[ 1190379-88-4 ]
[ 1190377-42-4 ]

Yield	Reaction Conditions	Operation in experiment
44%	With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide;	To a suspension of Intermediate 3 (35 mg, 0.10 mmol) in DMF (1 ml), was added thiazoIe-5- carboxylic acid (20.1 mg, 0.16 mmol), HATU (63.1 mg, 0.17 mmol) and N, N- diisopropylethylamine (108 mul, 0.62 mmol), and the resulting solution was stirred overnight. The volatiles were removed under reduced pressure and the crude product was re-dissolved in 1 :9 methanol : DCM (1 ml) and eluted through an Isolute-NH2 cartridge. After solvent removal, the crude product was purified by preparative LCMS (low pH buffer). After solvent removal, the product was re-dissolved in methanol/DCM (1:9) and eluted through an Isolute-NH2 cartridge and solvents evaporated to give a solid (19 mg, 44%). 1H NMR (400 MHz, CDCl3) delta ppm 0.41 - 0.60 (m, 2 H), 0.90 - 0.96 (m, 2 H), 1.42 - 1.50 (m, 1 H), 1.92 - 2.02 (m, 2 H), 3.51 - 3.72 (m, 2 H), 3.51 - 3.72 (m, 2 H), 5.87 (t, J=6.2 Hz, 1 H), 6.43 (t, ./=5.7 Hz, 1 H), 6.64 (td, ./=8.1, 2.1 Hz, 1 H), 6.92 <n="125"/>(br. s, 1 H), 7.03 (d, /=6.9 Hz, 1 H), 7.16 - 7.24 (m, 1 H), 7.77 (s, 1 H), 7.82 (dt, J=12.4, 2.3 Hz, 1H), 8.19 (s, 1 H), 8.88 (s, 1 H); m/z (ES+APCI)+: 413 [M+H]+.

Reference： [1]Patent: WO2009/122180,2009,A1 .Location in patent: Page/Page column 123-124

25
[ 14527-41-4 ]
(R)-2-amino-N-(biphenyl-3-yl)-7-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)heptanamide [ No CAS ]
C₂₉H₃₆BN₃O₄S [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 2909 - 2922

26
[ 14527-41-4 ]
(S)-2-amino-N-(biphenyl-3-yl)-7-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)heptanamide [ No CAS ]
C₂₉H₃₆BN₃O₄S [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 2909 - 2922

27
[ 14527-41-4 ]
[ 1150698-06-8 ]
[ 1150697-76-9 ]

Reference： [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 2909 - 2922

28
[ 14527-41-4 ]
[ 1165801-47-7 ]
[ 891262-09-2 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 3081 - 3084

29
[ 14527-41-4 ]
[ 1199814-68-0 ]
[ 1174651-15-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 3204 - 3208

30
[ 288-47-1 ]
[ 124-38-9 ]
[ 14527-41-4 ]
[ 14190-59-1 ]

Reference： [1]Journal of the American Chemical Society,2010,vol. 132,p. 8858 - 8859

31
[ 14527-41-4 ]
[ 870-46-2 ]
[ 1254073-84-1 ]

Yield	Reaction Conditions	Operation in experiment
		1 ,3-<strong>[14527-41-4]thiazole-5-carboxylic acid</strong> (0.5 g, 3.87 mmol, commercially available from e.g. Apollo) was suspended in dry dichloromethane (DCM) (10 ml_) under an atmosphere of argon before adding EDC (0.891 g, 4.65 mmol), followed by HOBt (0.296 g, 1.936 mmol) and stirring for 45 mins before adding 1 ,1-dimethylethyl hydrazinecarboxylate (0.614 g, 4.65 mmol) and stirring overnight at RT. The reaction was worked up by diluting with DCM (25 ml), washing with saturated sodium bicarbonate solution (25 ml). The aqueous layer was then extracted with DCM (2 x 25 ml) and the combined organic extracts were then washed with saturated brine solution (20ml), dried over MgSO4, filtered and evaporated to afford a yellow gum of crude product which was purified on a 100g SNAP cartridge eluting with DCM (3CV) to 100% 20% MeOH/DCM over 12 CV. The desired fractions was isolated and solvent evaporated to afford a colourless gum, which solidified overnight of desired product in 666 mg. LCMS m/z 243.98 (at) 0.61 min (2 min run).

Reference： [1]Patent: WO2010/125102,2010,A1 .Location in patent: Page/Page column 114

32
[ 14527-41-4 ]
[ 95-54-5 ]
[ 90765-94-9 ]

Reference： [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 7739 - 7755

33
[ 14527-41-4 ]
[ 1308655-78-8 ]
[ 1266338-22-0 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 1106 - 1110

34
[ 14527-41-4 ]
C₁₆H₁₇FN₂ [ No CAS ]
[ 1332336-62-5 ]